Allergy Therapeutics Share Discussion Threads

[qackers] 20/11/2014 15:14

Positive noises at AGM perhaps

[aruntim] 20/11/2014 11:05

Please I really need my cash out by Summer '15

[farmer george] 20/11/2014 10:52

It all looks encouraging jimmyloser. Let's hope they can now start to deliver.

[jimmyloser] 20/11/2014 10:06

The Company is expanding its infrastructure into the Emerging markets.
'nuff said!

Abbotts director on board - lol

[jimmyloser] 19/11/2014 08:24

AGM today at 11am

[jimmyloser] 18/11/2014 09:03

I should think so - this has Abbott written all over it now ! impo

[jimmyloser] 18/11/2014 08:07

Now - GLOBAL !!

"which will be invaluable to our Company as we continue to execute our (global) strategy."

[jimmyloser] 18/11/2014 07:03

18 November 2014

Allergy Therapeutics plc

("Allergy Therapeutics" or the 'Company")

Appointment of a Non-Executive Director

Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, is pleased to announce that it has appointed, with immediate effect, Jean-Yves Pavée as a Non-Executive Director; nominated by Abbott (NYSE: ABT).

Jean-Yves Pavée is Senior Vice President, Developed Markets for Abbott's Established Products Division. He was appointed to his role in July 2013. Previously, he served as Divisional Vice President, EMEA East, and Division Vice President, Pharmaceuticals, Europe South. He joined Abbott in 1992.

Peter Jensen Chairman of Allergy Therapeutics commented:

"We are delighted towelcome Jean-Yves to the Board. He brings extensive industry experience, which will be invaluable toour Company as we continue to execute our global strategy."

Additional information regarding Jean-Yves Pavée:

Full name and age: Jean-Yves Frédéric Georges André Pavée-Callu, aged 51

There are no further disclosures required under Schedule Two paragraph (g) of the AIM rules.

[jimmyloser] 04/11/2014 07:23

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Appointment of Dr Daphne Tsitoura as Head of Clinical Science
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces the appointment of Dr Daphne Tsitoura as Head of Clinical Science leading the Clinical Development team in Munich and Worthing from the 10th November, reporting to Professor Tim Higgenbottam.

Dr Tsitoura joins Allergy Therapeutics from GSK, where she has spent the last eight years as Principal Physician in the Respiratory Therapeutic Area in the GSKs' Stevenage Research Centre UK and has maintained a clinical link with allergy as an associate Allergist at University College Hospital London UK.

Previously she has held roles of Principal Immunologist at the Institute of Biomedical Research Academy of Athens, Consultant Physician / Chief of the Allergy Unit at the Henry Dunant Hospital Athens, senior fellow in immunology and allergy at Stanford University School of Medicine Palo Alto USA, and associate professor in Respiratory Medicine College of Physicians and Surgeons Columbia University New York.

Tim Higenbottam, R & D Director said:

"With an impressive career in medicine development and allergy, Daphne brings to Allergy Therapeutics a passion and drive to enhance the ease of use of allergy vaccines. She has a great depth of understanding of the therapeutic methods of modulation of the innate immune system to optimise allergy therapies. Her expertise will lend enormous support and strengthen our team of pharmaceutical experts and drive the research to gain approval of our Pollinex Quattro ultra-short course allergy vaccines in Europe and US."

[audigger] 04/11/2014 07:13

Well its certainly an interesting appointment. However, I can't help but think its in response to the last couple of years impasse especially in the US where little appears to have happened since the clinical trial hold was lifted. Hopefully this will drive things forward. but you have to wonder at what pace? Still lots of potential here but they need to crack-on and deliver before somebody else beats them to it

[jimmyloser] 27/10/2014 07:49

I find the note to editors interesting with its recently changed wording.

Note the use of the words and context of 'infrastructure' and 'distributors' and how expansion into emerging markets (USA?) is with 'infrastructure' and not 'distributors'!

impo/dyor

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

[audigger] 23/10/2014 16:48

Interesting little jump today!

[audigger] 16/10/2014 17:13

Seems to be a familiar pattern with AGY.

[algernon2] 16/10/2014 10:59

Hardly "glowing int he dark" at the moment eh Cube.Slightly disappointing downward motion.

[jimmyloser] 07/10/2014 16:33

Cube,
I agree. It was interesting that they only issued positive noises on the USA though.

How do you view the presence of Abbott on the scene?

[cube boss] 07/10/2014 14:10

Back to normal! no news with results and down we go!.
Need the US deal or the same pattern every 6 months..GLA ;0))

[jimmyloser] 06/10/2014 08:12

Not long for Allergy as we know it Jim??

[farmer george] 02/10/2014 18:16

No problem with that, but why drop reference to the GBP45.7 million figure? Of course, a higher figure would be good,.

[jimmyloser] 02/10/2014 17:46

It means that they are signalling that they are ramping up in the USA as I read it.

I am not ramping up though. lol,

Patience as the Cube would say.

[farmer george] 02/10/2014 17:27

...does that mean the earlier cited number of GBP45.7 million will be under-shot or, indeed, exceeded? We wait.

[jimmyloser] 02/10/2014 15:54

The Company is expanding its infrastructure into the Emerging Markets.

[farmer george] 02/10/2014 15:52

Hmmmm...no forecast for 2014?

[jimmyloser] 02/10/2014 15:34

This was September 4th 2014

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with expected revenue of GBP45.7million, before milestones and rebates and supported by a foreign exchange benefit of GBP2.3million, an increase of 14% on the previous year (2013:GBP39.9milllion) achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This was this week - spot the important difference

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of almost GBP40 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

[jimmyloser] 01/10/2014 15:50

It will be very interesting to see if these loose shares are mopped up later!